OCT Agreement and Crossed Precision Study

September 25, 2014 updated by: Nidek Co. LTD.

Crossed Precision Design Study of the Nidek Optical Coherence Tomography RS-3000, RS-3000 Lite and RS-3000 Advance for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, and Pachymetry

The purpose of this study is to asses the agreement of the RS-3000 Lite and RS-3000 Advance to the RS-3000, assess the crossed precision of each study device and to assess the transference of a reference database from the RS-3000 to the RS-3000 Lite and to the RS-3000 Advance.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

119

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Santa Ana, California, United States, 92705
        • WCCT Global Opthalmology Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Clinic subjects, general population

Description

Inclusion Criteria: NORMAL EYES

  • Subjects who do not have pathology in both eyes

Inclusion Criteria: GLAUCOMA

  • Subjects who have a glaucoma diagnosis

Inclusion Criteria: RETINAL

  • Subjects who have a retinal diagnosis including but not limited to:

    1. Diabetic macular edema
    2. Dry age related macular degeneration
    3. Wet age related macular degeneration
    4. Cystoid macular edema
    5. Epiretinal membrane
    6. Macular hole

Inclusion Criteria: CORNEAL

  • Subjects who has one of these diagnosis:

    1. Post status LASIK surgery
    2. Keratoconus
    3. Other corneal dystrophies or degenerations.

Exclusion Criteria: ALL EYES

  • Subjects who have any of the following conditions

    1. Diabetes mellitus (DM) and/or diabetic retinopathy
    2. Uncontrolled Hypertension (HT)
    3. Cerebral infarction, cerebral hemorrhage, cranial nerve neoplasm and other central nervous system diseases affecting vision
    4. Cardiac, hepatic, renal and hematologic diseases
    5. A current condition requiring systemic administration of steroid
    6. A history of, or currently receiving, anticancer therapy
    7. Epileptic seizures which are optically induced
    8. Dementia
  • Subjects who have other life threatening and debilitating systemic diseases

Note: Additional criteria may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Normal eyes
Eyes without pathology.
Glaucoma
Eyes with Glaucoma.
Retinal
Eyes with Retinal Disease.
Corneal
Eyes with corneal disease including a kerato-refractive group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retinal thickness
Time Frame: Approximately four hours
Time frame is the maximum duration of hospital stay
Approximately four hours
Optic Disc Analysis
Time Frame: Approximately four hours
Time frame is the maximum duration of hospital stay
Approximately four hours
Corneal Thickness
Time Frame: Approximately four hours
Time frame is the maximum duration of hospital stay
Approximately four hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nidek Co. LTD.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

January 22, 2014

First Submitted That Met QC Criteria

January 30, 2014

First Posted (Estimate)

January 31, 2014

Study Record Updates

Last Update Posted (Estimate)

September 29, 2014

Last Update Submitted That Met QC Criteria

September 25, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RS-3000 series Protocol 1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe